Add to Basket
|+1 404 474 4654|
|+1 888 205 9894 (TF)|
Kinase insert Domain Receptor (A Type III Receptor tyrosine Kinase) (KDR) (AA 20-764) antibody
|Synonyms||Flk1, Ly73, Flk-1, Krd-1, VEGFR2, VEGFR-2, sVEGFR-2, 6130401C07, FLK1, CD309, VEGFR, Vegfr-2, MGC93590, KDR, FLK-1, flk-1, vegfr-2|
Alternatives ELISA, Immunofluorescence (IF), Flow Cytometry (FACS), Western Blotting (WB)
|1 reference available|
|Price||363.00 $ Plus shipping costs $45.00|
|Availability||Will be delivered in 3 to 4 Business Days|
|Immunogen||Purified recombinant extracellular fragment of human KDR (AA 20-764) fused with hIgGFc tag expressed in HEK293 cells.|
KDR has also been designated as VEFR-2 (Vascular endothelial growth factor receptor 2), CD309 (cluster of differentiation 309) and Flk1 (fetal liver kinase 1). Vascular endothelial growth factor (VEGF) is a major growth factor for endothelial cells. KDR is one of the two receptors of the VEGF. This receptor, known as kinase insert domain receptor, is a type III receptor tyrosine kinase. It functions as the main mediator of VEGF-induced endothelial proliferation, survival, migration, tubular morphogenesis and sprouting. The signalling and trafficking of this receptor are regulated by multiple factors, including Rab GTPase, P2Y purine nucleotide receptor, integrin alphaVbeta3, T-cell protein tyrosine phosphatase, etc. Mutations of this gene are implicated in infantile capillary hemangiomas.
Synonyms: FLK1, CD309, VEGFR, VEGFR2
Western Blotting: 1/500 - 1/2000.
Immunofluorescence: 1/200 - 1/1000.
Flow cytometry: 1/200 - 1/400.
ELISA: Propose dilution 1/10000.
Not yet tested in other applications.
Determining optimal working dilutions by titration test.
|Buffer||Ascitic fluid containing 0.03% sodium azide.|
|Preservative||0.03% sodium azide|
|Storage||Store at 4℃, for long term storage, store at -20℃.|
|Restrictions||For Research Use only|
Lee, Bone, Strege et al.: "VEGF receptor phosphorylation status and apoptosis is modulated by a green tea component, epigallocatechin-3-gallate (EGCG), in B-cell chronic lymphocytic leukemia." in: Blood, Vol. 104, Issue 3, pp. 788-94, 2004 (PubMed).